XTANDI for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 23 adverse event reports in the FDA FAERS database where XTANDI was used for Neoplasm malignant.
Most Reported Side Effects for XTANDI
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Malignant neoplasm progression | 235 | 16.9% | 110 | 34 |
| Death | 234 | 16.8% | 234 | 13 |
| Fatigue | 162 | 11.6% | 19 | 18 |
| Drug ineffective | 158 | 11.3% | 7 | 11 |
| Prostatic specific antigen increased | 94 | 6.8% | 5 | 7 |
| Nausea | 69 | 5.0% | 5 | 13 |
| Asthenia | 62 | 4.5% | 5 | 13 |
| Decreased appetite | 56 | 4.0% | 12 | 8 |
| Dizziness | 52 | 3.7% | 2 | 6 |
| Diarrhoea | 51 | 3.7% | 3 | 12 |
| Back pain | 41 | 2.9% | 6 | 10 |
| Malaise | 41 | 2.9% | 4 | 9 |
| Arthralgia | 36 | 2.6% | 5 | 5 |
| Investigation | 31 | 2.2% | 6 | 31 |
| Dyspnoea | 30 | 2.2% | 2 | 13 |
Other Indications for XTANDI
Prostate cancer (787)
Product used for unknown indication (384)
Prostate cancer metastatic (135)
Hormone-refractory prostate cancer (8)
Bone cancer (6)
Neoplasm prostate (6)
Ill-defined disorder (5)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)